Palatin Technologies

Palatin Technologies

Palatin Technologies is a publicly traded biotechnology company (AMEX: PTN) headquartered in Cranbury, New Jersey. The firm was co-founded by scientists and has historically focused on peptide drug discovery. The company's strategy centers on developing first-in-class therapeutics based on melanocortin and natriuretic peptide receptor agonists. Their pipeline includes bremelanotide for female sexual dysfunction, which gained FDA approval in 2019 as Vyleesi (per FDA, June 2019). Additional programs target obesity, diabetic nephropathy, and rare diseases. The company operates through internal R&D and partnerships. As of fiscal year 2023, the firm reported under $5 million in revenue and had a market capitalization around $50 million (per SEC filings, 2023). The company has not disclosed total assets under management, given it is a product-development entity. No additional offices or philanthropic vehicles are publicly reported. The firm's structural differentiator is its specialization in peptide chemistry and melanocortin receptors, a niche area within biotech. This focus shapes its outsourcing partnerships and clinical trial design, distinguishing it from broader drug developers.